ERBB2 and gastric cancer: The adoption of minimally invasive surgery and endoscopic treatment techniques [22] and novel anti-HER2 therapeutic drugs, such as T-DXd and disitamab vedotin (RC48), has further led to significant advances in the treatment of gastric cancer [23].